NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis $15.81 +0.64 (+4.22%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$15.78 -0.03 (-0.19%) As of 08/22/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mesoblast Stock (NASDAQ:MESO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mesoblast alerts:Sign Up Key Stats Today's Range$15.14▼$15.9150-Day Range$10.16▼$16.9852-Week Range$6.00▼$22.00Volume162,232 shsAverage Volume151,117 shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. Read More Mesoblast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreMESO MarketRank™: Mesoblast scored higher than 42% of companies evaluated by MarketBeat, and ranked 681st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingMesoblast has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMesoblast has only been the subject of 2 research reports in the past 90 days.Read more about Mesoblast's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.70) to ($0.32) per share.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mesoblast's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.29% of the float of Mesoblast has been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Mesoblast has recently decreased by 12.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.29% of the float of Mesoblast has been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Mesoblast has recently decreased by 12.50%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.76 News SentimentMesoblast has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mesoblast this week, compared to 4 articles on an average week.Search Interest3 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address MESO Stock News HeadlinesMESO | Mesoblast Ltd. ADR Annual Income Statement | MarketWatchAugust 14, 2025 | marketwatch.comUlcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline | DelveInsightAugust 13, 2025 | theglobeandmail.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.August 23 at 2:00 AM | American Alternative (Ad)JPMorgan Acquires Substantial Stake in MesoblastJuly 23, 2025 | msn.comMesoblast shares surge on strong Ryoncil launch, tapering off after Friday rallyJuly 21, 2025 | proactiveinvestors.comWhy Mesoblast shares can keep storming higherJuly 21, 2025 | msn.comMesoblast stock soars after reporting first Ryoncil salesJuly 19, 2025 | investing.comSuccessful Commercial Launch of Ryoncil®July 17, 2025 | globenewswire.comSee More Headlines MESO Stock Analysis - Frequently Asked Questions How have MESO shares performed this year? Mesoblast's stock was trading at $19.80 at the start of the year. Since then, MESO shares have decreased by 20.2% and is now trading at $15.81. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) announced its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. The company earned $2.14 million during the quarter, compared to the consensus estimate of $2 million. Read the conference call transcript. When did Mesoblast's stock split? Shares of Mesoblast reverse split on Friday, January 5th 2024.The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's top institutional shareholders include Summit X LLC (0.16%), Group One Trading LLC, Marex Group plc and Lazari Capital Management Inc. (0.04%). How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings8/30/2023Today8/23/2025Next Earnings (Estimated)8/27/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees80Year Founded2004Price Target and Rating Average Price Target for Mesoblast$18.00 High Price Target$24.00 Low Price Target$12.00 Potential Upside/Downside+13.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.22 Current Ratio0.96 Quick Ratio0.63 Sales & Book Value Annual Sales$5.90 million Price / Sales343.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.21 per share Price / Book3.76Miscellaneous Outstanding Shares128,000,000Free Float103,934,000Market Cap$2.02 billion OptionableOptionable Beta2.40 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:MESO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.